R Squared’s Terns Pharmaceuticals TERN Stock Holding History

R Squared’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,130	Closed	-$6.26K	–	1387
2024 Q4	$6.26K	Buy	+1,130	New	+$7.65K	0.01%	1270

Other funds holding TERN

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

R Squared's TERN Position: Q1 2025 in Review

R Squared sold out of Terns Pharmaceuticals (TERN) in Q1 2025, closing a stake of 1,130 shares — an estimated $6.26K sold.

R Squared first reported a position in TERN in Q4 2024 and held it in 1 quarter. The position peaked at $6.26K in Q4 2024. 137 funds tracked by Wall St. Rank hold TERN as of Q1 2025.

R Squared reported no remaining Terns Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,130 Terns Pharmaceuticals shares in Q1 2025, an estimated $6.26K.
R Squared first reported a position in Terns Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Terns Pharmaceuticals position peaked at $6.26K in Q4 2024.
137 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.